Mitochondria as a target of third row transition metal-based anticancer complexes.
Mitochondria as a target of third row transition metal-based anticancer complexes.
复制标题
DOI：
10.1016/j.cbpa.2022.102235
复制
发表时间：
2022-12
影响因子：
7.8
通讯作者：
Chibuzor Olelewe;Samuel G. Awuah
中科院分区：
文献类型：
--
作者：
Chibuzor Olelewe;Samuel G. Awuah
为了寻求更好的治疗恶性肿瘤的选择，金属基配合物继续显示出作为有吸引力的化疗药物的前景，由于可调谐性，新的机制，和以铂剂为例的效力。肿瘤的代谢特征使线粒体和其他代谢途径成为药物无机化学的有效靶点。对线粒体在肿瘤发生中的作用的累积理解点燃了对线粒体靶向金属基复合物的研究，以克服抗性并以高效力和选择性抑制肿瘤生长。在这里，我们讨论了第三行过渡金属为基础的线粒体靶向药物的最新进展，目的是刺激一个积极的研究领域，向新的临床抗癌药物和阐明新的作用机制。
In pursuit of better treatment options for malignant tumors, metal-based complexes continue to show promise as attractive chemotherapeutics due to tunability, novel mechanisms, and potency exemplified by platinum agents. The metabolic character of tumors renders the mitochondria and other metabolism pathways fruitful targets for medicinal inorganic chemistry. Cumulative understanding of the role of mitochondria in tumorigenesis has ignited research in mitochondrial targeting metal-based complexes to overcome resistance and inhibit tumor growth with high potency and selectivity. Here, we discuss recent progress made in third row transition metal-based mitochondrial targeting agents with the goal of stimulating an active field of research toward new clinical anticancer agents and the elucidation of novel mechanisms of action.